ArticleFrontiers in immunology2025
SLC12A7 serves as a prognostic and immunotherapeutic biomarker identified by multi-omics analysis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating multiple omics and machine learning to reveal the prognostic value of endoplasmic reticulum stress geneTranslational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Solute carrier family 12 member 7 (SLC12A7) is a membrane transporter implicated in ion homeostasis. Recent studies have suggested its aberrant expression in various malignancies; however, its functional roles and clinical relevance across cancers remain poorly defined. Given the limited understanding of SLC12A7 in oncogenesis and the urgent need for novel biomarkers, particularly in hepatocellular carcinoma (HCC), we conducted a comprehensive pan-cancer analysis to elucidate its potential oncogenic roles. Methods: Transcriptomic and clinical data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), cBioPortal, TIMER 2.0, and Gene Expression Omnibus (GEO) were integrated to investigate the expression patterns, prognostic significance, genetic alterations, and immune correlations of SLC12A7. Single-cell RNA sequencing data were analyzed to examine its heterogeneity within the tumor microenvironment. Functional enrichment analyses were performed to identify associated signaling pathways. Results: SLC12A7 was significantly upregulated in multiple cancer types and correlated with unfavorable clinical outcomes. Single-cell analysis revealed its enrichment in malignant cell populations and its involvement in the regulation of the tumor microenvironment. SLC12A7 expression was associated with immune cell infiltration and immune checkpoint gene expression. Functional assays confirmed that SLC12A7 enhances HCC cell proliferation, migration, and invasion. Conclusions: These findings identify SLC12A7 as a potential prognostic biomarker and immunotherapeutic target across cancers. Its oncogenic role in HCC suggests clinical utility in guiding prognosis and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.